Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

Biotechnology

Healthcare
$7.06 -2.70%

-$0.26 today

Market cap
$618.50M
Beta
2.00
P/E (TTM)
-5.1
EPS (TTM)
-$1.80
52W Low $4.02High $36.26

Volume 1.18M

Average 1.27M

OLMA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Olema Pharmaceuticals, Inc.NASDAQ: OLMA

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $49.23M rose 60.8% year over year, ahead of the +40.8% change in trailing-twelve-month research & development. Sequentially, it rose 13.9% from the prior quarter. Over 3 fiscal years it compounded at +24.2% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +60.8% holds above the trailing-twelve-month pace of +40.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$49.23M+13.9% QoQ
Last fiscal yearDec 2025
$157.7M+26.6% YoY
LTMMar 2026
$176.31M+40.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+60.8%——
1 year+26.6%——
3-year CAGR+24.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
157.7M USD
Year-over-year change
+26.6%
4-year CAGR
+32.5%

Research & Development vs competitors

How OLMA compares with its peers on the latest reported figures

  • OLMA's LTM Mar 2026 research & development of $176.31M is the highest of the 2 companies compared; the peer median is $68M.
  • Its year-over-year change of +40.8% is the highest of 2, against a peer median of +23.2%.
  • Over three fiscal years its annual growth of +24.2% compares with a peer median of +5.9%.
OLMA Competitors Peer median
Research & Development for OLMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$176.31M +40.8%+24.2%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$68M +23.2%+5.9%29.9%
Peer median (excluding OLMA) $68M+23.2%+5.9%29.9%

Competitors are the stored peer set for OLMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development51.1M82.27M86.14M124.52M157.7M
Selling, General & Admin20.39M24.71M18.82M17.74M21M
Operating Expenses71.49M106.99M104.96M142.26M178.7M
Depreciation & Amortization163K357K377K393K490K
EBITDA(70.93M)(104.43M)(96.28M)(129.08M)(161.96M)
EBITDA Margin—————
Operating Income(71.49M)(106.99M)(104.96M)(142.26M)(178.7M)
Operating Margin—————
Interest Income442K2.23M8.32M12.68M16.22M
Interest Expense—0—00
Other Income / Expenses395K2.2M8.31M12.78M16.25M
Income Before Tax(71.1M)(104.79M)(96.66M)(129.47M)(162.45M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(71.1M)(104.79M)(96.66M)(129.47M)(162.45M)
Net Margin—————
EPS (Basic)(1.79)(2.62)(2.14)(2.20)(1.87)
EPS (Diluted)(1.79)(2.62)(2.14)(2.20)(1.87)
Weighted Avg Shares39.52M40M45.25M58.74M87.01M
Weighted Avg Shares (Diluted)39.52M40M45.25M58.74M87.01M

Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

Intrinsic Alpha fair value

Locked

Current Price

$7.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.